Because APOE locus variants contribute to risk of late-onset Alzheimer disease (LOAD) and to differences in age at onset (AAO), it is important to know whether other established LOAD risk loci also affect AAO in affected participants.
but only variation in the APOE region has been consistently confirmed. [8] [9] [10] [11] [12] A multitude of studies have attempted to identify susceptibility genes for AAO in AD. The first study 13 to identify a genetic association with AAO showed a lower mean AAO among affected participants with AD for each additional copy of the ε4 allele at the APOE locus on chromosome 19q (84.3 years for 0 copy, 75.5 years for 1 copy, and 68.4 years for 2 copies), a finding that has since been replicated. 14 Subsequent genome-wide linkage scans examining AAO in patients with AD and unaffected family members (using age at study entry) found suggestive evidence of linkage on chromosome 19 to APOE (logarithm of odds [LOD], 3.28), 15 which was confirmed in later investigations. 16 Multiple studies identified other suggestive linkage signals on chromosomes 4q, 8q, 1q, 6p, 7q, 15, and 19p [16] [17] [18] in families of white race/ethnicity and on chromosomes 5q, 7q, 14q, and 17q 19 in Caribbean Hispanics, although the specific loci driving these linkage signals remain unknown. More recently, an A AO genome-wide association study 2 0 (GWAS) in 2222 AD patients of white race/ethnicity confirmed an association at APOE and found strong evidence of association (P = 5.0 × 10 −7 ) on chromosome 4q31.3 in the DCHS2 gene. The lack of overlap in the regions identified across these studies may have resulted from differences in the approaches applied such as varied strategies for censoring unaffected pedigree members and differences in covariates adjusted for in analyses. Reduced statistical power from the limited availability of extended families for analysis may also have contributed to the differences in findings between these early linkage and association studies. The high variability in approaches and findings highlights the need for a more comprehensive approach to identify genetic risk factors that may influence LOAD AAO, as well as LOAD risk directly. To date, variants in the 10 confirmed LOAD risk loci have not been examined for their possible influence on AAO among affected participants with LOAD.
Using data from 9162 affected participants with LOAD from a GWAS of LOAD by the Alzheimer Disease Genetics Consortium (ADGC), 6 we examined whether variants most significantly associated with LOAD risk in 10 LOAD loci are also associated with differences in AAO among affected participants with LOAD. Furthermore, we used a genetic burden analysis approach to determine the proportion of variation in AAO accounted for by variants in these established LOAD risk genes.
Methods

Ascertainment and Collection of Genotype and Phenotype Data
The ADGC comprises 14 case-control, prospective, and familybased data sets with data on 9162 participants of white race/ ethnicity with AD occurring after age 60 years who also had complete AAO information, gathered between September 1989 and January 2011 at multiple sites by participating studies. 
Statistical Analysis
We performed association analysis on individual data sets assuming an additive model on log-transformed AAO with covariate adjustment for population substructure. For cases from case-control data sets, linear regression was performed in PLINK, 22 while for analysis of cases from family data sets (used only in the primary analysis of risk variants), generalized estimating equations with a linear model as implemented in a statistical package (R; http://www.r-project.org/) 25 were used.
To account for the effects of population substructure, we performed a principal components analysis on affected participants within each data set (using EIGENSTRAT; http://genepath .med.harvard.edu/~reich/EIGENSTRAT.htm) 26 on a subset of 21 109 SNPs common to all genotyping platforms. The first 3 principal components from the analysis were incorporated in our minimal model for covariate adjustment. We also performed analyses conditioning on the major AAO-modifying effects of APOE through an extended model of covariate adjustment that included sex and the number of APOE ε4 alleles (0, 1, or 2). Results from individual data sets were combined in the meta-analysis using inverse variance weighting (as implemented in METAL; http://www.sph.umich.edu/csg/abecasis /metal/), 27 applying a genomic control to each data set. With this set of 9162 affected participants, for 10 focused independent hypothesis tests, we expected to have greater than 80% power to detect loci at α = 0.05 with as little effect as 5 months' difference in AAO per allelic copy for very common variants (MAF, 0.30), and greater than 80% power to detect 8 months' difference in AAO per allelic copy for variants of modest or low frequency (MAF, 0.10).
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Because of limitations in the availability of genotyped replication data sets with similar AAO phenotypes and ascertainment, we performed a discovery genome-wide association meta-analysis among 6143 cases in 10 ADGC case-control data sets to determine whether SNPs with weak or no LOAD risk associations may contribute to differences in AAO, as well as to assess the genetic burden attributable to these variants. Methods, results, and a brief summary are provided in the eAppendix, eFigure, and eTables 5-9 in the Supplement. Replication data on affected participants from 6 new ADGC data sets (described in the Methods subsection of the eAppendix in the Supplement) were also examined.
In addition to association meta-analysis, we performed several genetic burden analyses to determine the percentage contribution of LOAD susceptibility SNPs in 10 LOAD candidate genes to variation in AAO. Risk-weighted genetic burden analyses of AAO linearly modeled locus-specific effects as the product of the meta-analysis-estimated LOAD risk (across-study change in AAO for each copy of the minor allele) and the dosage of the minor allele (scale, 0-2; estimated from genotype-specific imputation probabilities) and were implemented in analyses of risk variants. Additional covariate adjustment in the burden model included covariates for population substructure from principal components analysis and data set-specific effects. We also performed a score-based genetic burden analysis of AAO using a risk genotype score derived from summing dosages of the risk alleles at the 10 LOAD risk loci examined.
Results
ADGC Data Characteristics
Descriptive characteristics of the individual ADGC data sets are summarized in eTable 1 in the Supplement. There were more female affected participants (5480 [59.8%]) than male affected participants. The mean (SD) AAO was 74.3 (7.6) years for the entire group. Several data sets had later ages at onset ( Figure) . Two of these were population-based cohorts of aging and memory loss, Religious Orders Study/Memory and Aging Project (mean [SD] AAO, 85.6 [6.3] years) and Adult Changes 
LOAD Susceptibility Variant Associations With AAO
We confirmed an association of the APOE ε4 allele with lower AAO, with each additional copy of the ε4 allele reducing AAO by 2.45 years (β = −2.45, P = 3.3 × 10 −96 ). Examining the variants most strongly associated with LOAD in 9 genomic regions with genome-wide statistically significant associations in our GWAS of LOAD risk ( Table 1) , 6 we observed that several LOAD risk loci also demonstrated statistically significant associations (P < .005) with AAO, including rs6701713 in CR1 (P = 7.2 × 10 ). Both rs6701713 in CR1 and rs7561528 in BIN1 demonstrated a reduced AAO for each copy of the risk variant, with each copy of the risk allele A at rs6701713 (MAF, 0.24) advancing AAO by approximately 5 months (β = −0.41; 95% CI, −0.65 to −0.17) and with each copy of the risk allele A at rs7561528 (MAF, 0.37) advancing AAO by slightly less than 4 months (β = −0.31; 95% CI, −0.52 to −0.09). In contrast, each copy of the more common risk allele A (frequency, 0.62) at rs561655 in the PICALM gene corresponded with earlier onset by approximately 4 months (β = −0.33; 95% CI, −0.55 to 0.12). These patterns of association remained largely unchanged after adjustment for APOE ε4 allele dosage and sex for the CR1 variant (rs6701713; β = −0.41; 95% CI, −0.69 to −0.12; P = 4.9 × 10 −3 ) and for the BIN1 variant (rs7561528; β = −0.32; 95% CI, −0.57 to −0.08; P = 9.9 × 10 −3 ). While the size and direction of the association remained the same as in the minimally adjusted model, the association of the PICALM variant demonstrated only marginal significance after this additional adjustment (rs561655; β = 0.32; 95% CI, 0.07-0.57; P = .011). Investigation of AAO associations in the vicinity of these AD risk variants revealed no substantially different associations among nearby variants. Directions of variant effects were concordant between AD risk and AAO; all variants that increase risk also lower AAO. We examined these associations in a limited replication data set of 1978 cases from 6 newly available ADGC case-control data sets (described in the eAppendix in the Supplement). Although similar directionality of effects on AAO were observed for all the LOAD risk variants (eTable 2 in the Supplement), other than APOE, none of the AAO associations of CR1, BIN1, and PICALM variants in the replication data set of less than 2000 affected participants were nominally significant (P < .05). Power with these data are limited in a data set of 1978, and for a variant of MAF of 0.20, there is 80% power to detect at a difference in AAO of about 10 months at α = 0.05, whereas for a variant of MAF of 0.30, 80% power can detect a 9-month AAO difference.
Genetic Burden Analysis of AAO With LOAD Risk Variants
We examined the genetic burden of APOE and the LOAD risk variants in the 9 genomic regions on variation in AAO ( Table 2) in the 14 ADGC data sets with complete AAO data. In our base- Abbreviations: β, β Coefficient for age at onset from the meta-analysis (the number of years' difference in age at onset per copy of the minor allele); CH:MB, chromosome:position (in megabases, build 19); LOAD, late-onset Alzheimer disease; MAF, minor allele frequency; OR, odds ratio; P Value for Het, P value for heterogeneity across studies; SNP, single-nucleotide polymorphism. counted for by population substructure and study-specific effects. The independent contributions of dosage of the APOE ε4 allele to the genetic burden was roughly 3.7% of AAO variation (R 2 = 0.256), while the cumulative effect of the 9 LOAD risk variants was 2.2% (R 2 = 0.242), together accounting for approximately 5.6% of genetic variation in AAO (R 2 = 0.277). Excluding study-specific effects, APOE accounts for 4.8% of the remaining variation, and the 9 LOAD risk variants account for another 2.8%, for a combined contribution of 7.2% of the variation of AAO. Variant effects in burden modeling were consistent with the association results for individual variants described above.
To determine whether ascertainment differences may have influenced the amount of variation in AAO attributable to LOAD risk variants, we examined the effects of the 3 data sets with much later average AAO (Adult Changes in Thought, Oregon Health & Science University, and Religious Orders Study/Memory and Aging Project) and the 2 familybased data sets (National Institute on Aging-LOAD and Multi-Institutional Research on Alzheimer Genetic Epidemiology) on genetic burden analyses. In analyses that excluded the data sets with later average AAO (eTable 3 in the Supplement), we found that these data sets account for much of the data set-specific AAO variation, reducing the effect of data set on AAO variation from just over 22% to 2.5% (R 2 = 0.0251). In these analyses, after excluding data set-specific effects, the percentage variation attributable to APOE was slightly higher at 4.3% (R 2 = 0.0434), the effect attributable to the 9 LOAD risk variants was similar to before at 1.1% (R 2 = 0.0367), and the combined contribution of both was observed to be 5.5% (R 2 = 0.0799). Removal of the family data sets (eTable 4 in the Supplement) did not appreciably change the variation attributable to study-specific effects (R 2 = 0.225), nor did it substantially change the relative effects of APOE and the 9 LOAD risk variants on AAO variation. To determine the aggregate effect of risk alleles from the 10 LOAD loci, we also tested the association of a risk genotype score derived from summed unweighted dosages of the risk alleles at the 10 LOAD risk loci examined ( Table 3) . We observed that, for each risk allele copy at these 9 LOAD risk loci, there was a lower AAO of 1.8 months (β = −0.15; 95% CI, −0.24 to −0.07; P = 2.7 × 10 −4 ). Including APOE ε4 dosage, the combined effect of the 9 LOAD risk loci and APOE ε4 corresponded to a lower AAO of 4.2 months (β = −0.35; 95% CI, −0.43 to −0.27; P = 1.0 × 10 −17
) for each LOAD risk allele copy. Examining only the variants at CR1, BIN1, and PICALM that showed significant lowering of AAO, AAO is still lower for each risk copy (4.9 months) (β = −0.41; 95% CI, −0.54 to −0.27; P = 1.9 × 10 −9 ) and more so when APOE ε4 is included in the score (10.1 months) (β = −0.84; 95% CI, −0.96 to −0.73; P = 8. 4 × 10 −44 ).
Discussion
Our analysis of more than 9000 affected participants having LOAD with AAO information is the largest genetic study of LOAD AAO to date. Examining AAO associations at LOAD risk loci, we confirmed the association of APOE region variation with AAO and found additional strong associations with AAO among variants at 3 of the other 9 established risk loci (CR1, BIN1, and PICALM). Burden analysis demonstrated that the cumulative variation explained by SNPs at 9 LOAD risk loci was about one-third as much as the percentage variation in AAO from APOE. A risk genotype score analysis found that, in aggregate, each additional risk allele at the major LOAD loci lowers AAO by as much as 10 months per copy, emphasizing that the aggregate effect of these risk loci may lead to much earlier onset for some affected participants with LOAD. The APOE ε4 allele was observed to have a smaller effect on phenotype variation in AAO herein (3%-4%) than in some previous investigations (7%-9%) . 29 This may be owing to differences in study design; for instance, all previous estimates were made in pedigrees enriched in cases and often the APOE ε4 allele, whereas most affected participants examined herein were unrelated (only 2302 of 9162 affected participants [25.1%] were from family data sets). However, this deflation is consistent with several recent findings: 2 recent analyses using GWAS data found that the APOE ε4 allele contributed to 4% 30 and 6% 31 of the phenotype variation in LOAD risk, with which APOE ε4 is more strongly associated than AAO. In addition to confirming the predominance of the effect of APOE on AAO, we showed that the cumulative effects of risk loci associated with AAO may have an effect of similar scale on AAO. In our secondary analysis of genome-wide association, cumulative effects on the genetic burden of SNPs associated with AAO but with little or no effect on LOAD risk accounted for more variation in AAO compared with the non-APOE risk variants (2.2% vs 1.1%) but were still dwarfed by the effects of APOE on variation in AAO (approximately 4%).
The results of several previous studies have suggested potential associations of risk variants at these loci with AAO. A recent study 10 using a small subset of the cases used in this study (Alzheimer Disease Center 1, 2, and 3 [n = 2569] ) identified an association with a PICALM risk variant (rs3851179, P = .009). A study 32 of the expression of the 10 LOAD risk genes in parietal lobe neurons from an autopsy series of AD brains demonstrated nominally significant evidence of an association between reduced BIN1 expression levels and earlier AAO (P = .041), as well as an association with a longer duration of disease. A study by Jones et al 33 among persons with Down syndrome, which is typically associated with elevated AD risk at an earlier AAO, showed that risk variants in APOE (P = .014) and PICALM (P = .011) were correlated with lower AAO in patients with AD having Down syndrome. Daw et al 29 analyzed families with a high burden of AD and later AAO in a multiplex family data set and found evidence of at least 4 additional genes with major effects on variation in AAO as large as those of APOE. The lack of major AAOmodifying effects outside of APOE in our study is not consistent with the study by Daw et al and may reflect genetic heterogeneity of AAO genetics within LOAD or, more likely, may indicate the existence of large effect modifiers enriched in families with multiple affected members. APOE-related survival effects may have further complicated the identification of AAO-modifying genes. Furthermore, other genetic mechanisms, including the effects of rare variants, epigenetic modification, and gene-environment interactions, which have been reported to influence dementia risk and cognitive decline, [34] [35] [36] [37] [38] [39] may also contribute to variation in AAO of AD. The identification of other genetic modifiers of AAO through studies of larger samples of affected participants with LOAD and studies using next-generation sequencing approaches, which can more thoroughly interrogate the genome, may yield additional genetic risk factors that influence AAO and provide new insights into the pathogenesis of LOAD.
Conclusions
We confirmed an association of APOE variants with AAO among affected participants with LOAD and observed novel associations of CR1, BIN1, and PICALM with AAO. In contrast to earlier hypothetical modeling, we show that the combined effects of AD risk variants on AAO are on the scale of, but do not exceed, the APOE effect. While the aggregate effects of risk loci on AAO may be significant, additional genetic contributions to AAO are individually likely to be small. derived from the sum of genotype dosages for the risk-increasing allele from the 9 late-onset Alzheimer disease candidate loci, as well as the dosage of APOE ε4. Model 1 includes the sum of the genotype dosages for the 9 late-onset Alzheimer disease risk loci only. Model 2 also adds the number of APOE ε4 copies to the risk genotype score. Model 3 examines only the sum of the 3 variants associated with age at onset (variants at CR1, BIN1, and PICALM). Model 4 examines the CR1, BIN1, and PICALM variants and includes APOE ε4. Covariate adjustment in all 4 models includes the data set of origin and population substructure captured by the first 3 principal components from EIGENSTRAT (http://genepath.med.harvard.edu/~reich/EIGENSTRAT.htm).
